The impact of sarcopenia on the efficacy and safety of immune checkpoint inhibitors in patients with solid tumours.

Female Humans Immune Checkpoint Inhibitors Lung Neoplasms / drug therapy Male Progression-Free Survival Retrospective Studies Sarcopenia / chemically induced
Low muscle mass immune checkpoint inhibitors immune-related severe toxicity immunotherapy

Journal

Acta oncologica (Stockholm, Sweden)
ISSN: 1651-226X
Titre abrégé: Acta Oncol
Pays: England
ID NLM: 8709065

Informations de publication

Date de publication:
Dec 2021
Historique:
pubmed: 23 9 2021
medline: 15 12 2021
entrez: 22 9 2021
Statut: ppublish

Résumé

Evidence suggests that sarcopenia is a significant predictive factor of worst outcomes and treatment-associated toxicities in patients with metastatic solid tumours. The aim of this study was to explore the relationship between low muscle mass and clinical outcomes and immune-related severe toxicities (IrST) in patients treated with immune checkpoint inhibitors (ICIs). A retrospective cohort of 261 consecutive metastatic solid tumour patients treated with ICIs were included in our study. Low muscle mass was defined as skeletal muscle index <41 cm The majority of patients ( No difference in outcomes and safety was observed for low muscle mass and non-low muscle mass patients treated with ICIs.

Sections du résumé

BACKGROUND BACKGROUND
Evidence suggests that sarcopenia is a significant predictive factor of worst outcomes and treatment-associated toxicities in patients with metastatic solid tumours. The aim of this study was to explore the relationship between low muscle mass and clinical outcomes and immune-related severe toxicities (IrST) in patients treated with immune checkpoint inhibitors (ICIs).
METHODS METHODS
A retrospective cohort of 261 consecutive metastatic solid tumour patients treated with ICIs were included in our study. Low muscle mass was defined as skeletal muscle index <41 cm
RESULTS RESULTS
The majority of patients (
CONCLUSION CONCLUSIONS
No difference in outcomes and safety was observed for low muscle mass and non-low muscle mass patients treated with ICIs.

Identifiants

DOI: 10.1080/0284186X.2021.1978540 PMID: 34549686
pubmed: 34549686
doi: 10.1080/0284186X.2021.1978540
doi:

Substances chimiques

Immune Checkpoint Inhibitors 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1597-1603

Auteurs

Laura Haik (L)

Department of Medical Oncology, Hôpital Saint-André, CHU Bordeaux-University of Bordeaux, Bordeaux, France.

Aurore Gonthier (A)

Service d'information médicale, CHU, Bordeaux, France.

Amandine Quivy (A)

Department of Medical Oncology, Hôpital Saint-André, CHU Bordeaux-University of Bordeaux, Bordeaux, France.

Marine Gross-Goupil (M)

Department of Medical Oncology, Hôpital Saint-André, CHU Bordeaux-University of Bordeaux, Bordeaux, France.

Remi Veillon (R)

Department of Pneumology, Hôpital Haut-Leveque, CHU Bordeaux, Bordeaux, France.

Eric Frison (E)

Service d'information médicale, CHU, Bordeaux, France.

Alain Ravaud (A)

Department of Medical Oncology, Hôpital Saint-André, CHU Bordeaux-University of Bordeaux, Bordeaux, France.

Charlotte Domblides (C)

Department of Medical Oncology, Hôpital Saint-André, CHU Bordeaux-University of Bordeaux, Bordeaux, France.
University of Bordeaux, Bordeaux, France.
ImmunoConcEpt, CNRS UMR 5164, Bordeaux University, Bordeaux, France.

Amaury Daste (A)

Department of Medical Oncology, Hôpital Saint-André, CHU Bordeaux-University of Bordeaux, Bordeaux, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › The impact of sarcopenia on the efficacy and...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Antinéoplasiques immunologiques › Inhibiteurs de points de contrôle immunitaires › The impact of sarcopenia on the efficacy and...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › The impact of sarcopenia on the efficacy and...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Analyse de survie › Survie sans progression › The impact of sarcopenia on the efficacy and...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › The impact of sarcopenia on the efficacy and...
questionsmedicales.fr › États, signes et symptômes pathologiques › Signes et symptômes › Manifestations neurologiques › Manifestations neuromusculaires › Amyotrophie › Sarcopénie › The impact of sarcopenia on the efficacy and...